MNG520
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.523
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.457
- FATTY_ACID_METABOLISM+0.413
- ALLOGRAFT_REJECTION+0.387
- ADIPOGENESIS+0.373
- MYC_TARGETS_V1+0.372
- IL6_JAK_STAT3_SIGNALING+0.343
- DNA_REPAIR+0.324
- GLYCOLYSIS+0.314
- P53_PATHWAY+0.314
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.381
- MITOTIC_SPINDLE-0.309
- UV_RESPONSE_DN-0.207
- ESTROGEN_RESPONSE_EARLY-0.188
- KRAS_SIGNALING_DN-0.181
- APICAL_JUNCTION-0.127
- TGF_BETA_SIGNALING-0.124
- SPERMATOGENESIS-0.099
- ANDROGEN_RESPONSE-0.088
- G2M_CHECKPOINT-0.082
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 31550B35-DA39-4294-8368-811A412B2E3A | — | — | 0.847 |
| 2 | 551ADCCD-D116-43D8-AABC-E7E111D79E70 | — | — | 0.845 |
| 3 | TCGA-BA-A6DD-01A-12R-A31N-07 | — | — | 0.826 |
| 4 | 93708EED-CBE1-4B2E-A571-34316ACFE748 | — | — | 0.818 |
| 5 | BS_JG9JZTA9 | low-grade glioma | — | 0.816 |
| 6 | TCGA-05-4418-01A-01R-1206-07 | — | cohortA4 | 0.811 |
| 7 | 27875588-7C41-49BB-A4C0-A66D72A12499 | — | — | 0.809 |
| 8 | C884FB38-DE5C-48BA-95F1-4ABD2991E833 | — | — | 0.807 |
| 9 | FBB4DAFD-11F1-498F-95C5-73D8B735465B | — | — | 0.806 |
| 10 | cddceb59-733b-48d1-9b75-46c9949f7794 | — | — | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.523 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.457 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.413 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.387 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.373 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.372 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.343 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.324 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.314 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.314 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.292 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.280 | Idelalisib | — uncovered |
| COMPLEMENT | 0.277 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.271 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.251 | Binimetinib | — uncovered |
| APOPTOSIS | 0.235 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.226 | Idelalisib | — uncovered |
| PEROXISOME | 0.218 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.209 | Inavolisib | — uncovered |